Comparative Pharmacology
Head-to-head clinical analysis: INVANZ versus MERREM IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVANZ versus MERREM IV.
INVANZ vs MERREM IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1 g IV or IM once daily
1 g intravenously every 8 hours over 15-30 minutes for complicated intra-abdominal infections; 500 mg intravenously every 8 hours for complicated skin and skin structure infections.
None Documented
None Documented
Terminal elimination half-life approximately 4 hours; prolonged to approximately 8 hours in mild to moderate renal impairment (CrCl 30-59 mL/min) and to 14 hours in severe renal impairment (CrCl <30 mL/min); clinical context: requires dosage adjustment in renal impairment.
Terminal elimination half-life approximately 1 hour in adults with normal renal function; prolonged to 4–6 hours in moderate renal impairment and up to 10 hours in severe impairment; clinical context: dosing interval adjustment required for CrCl <50 mL/min.
Renal: ~80% unchanged in urine; biliary/fecal: ~10% as unchanged drug and the open-ring metabolite; minor hepatic metabolism.
Primarily renal (approximately 70% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for ~20% as microbiologically inactive metabolite; minimal nonrenal clearance.
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic